Get startedLog in
    Picture of Elicio Therapeutics logo

    ELTX — Elicio Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareMicro CapSucker Stock
    All News

    Elicio Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

    Picture of Elicio Therapeutics logoElicio Therapeutics
    14/05/2025 19:10
    Elicio Therapeutics Inc ELTX.OQ reported a quarterly adjusted loss of 87 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.15.  The mean expectation of three analysts for the quarter was for a loss of 83 cents per share. Wall Street expected results to range from $-1.15 to -64 cents per share.

Reported revenue was zero​; analysts expected zero.

Elicio Therapeutics Inc's reported EPS for the quarter was a loss of 87 cents​.

The company reported a quarterly loss of $11.21 million.

Elicio Therapeutics Inc shares had fallen by 7.3% this quarter and gained 12.0% so far this year.

FORECAST CHANGES

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Elicio Therapeutics Inc is $12.00

This summary was machine generated from LSEG data May 14 at 06:10 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)


    QUARTER ENDINGESTIMATEACTUALBEAT, MET, MISSED
    Mar. 31 2025-0.83-0.87Missed
    Dec. 31 2024-0.87-1.02Missed
    Sep. 30 2024-0.73-1.39Missed
    Jun. 30 2024-0.96-0.64Beat

    Recent news on Elicio Therapeutics

    See all news